Larisa V. Gubareva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Larisa V. Gubareva has a total of 296 co-authors. Here are the top co-authors by number of shared publications:
Vasiliy P. Mishin
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
23 shared publicationsHa T. Nguyen
Centers for Disease Control and Prevention
17 shared publicationsAnton Chesnokov
11 shared publicationsKatrina Sleeman
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , and
11 shared publicationsAlexander I. Klimov
9 shared publicationsAlicia M. Fry
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Collaborating Center for Surveillance, Epidemiology and Control of Influenza, Atlanta, Georgia, USA
8 shared publications
Latest Publications
- Open Access
Comparative immunogenicity and relative vaccine efficacy of recombinant and cell culture-based influenza vaccines: Results from a randomized trial of adults in the United States, 2024-2025
Background: Recombinant (RIV) and cell culture-based inactivated (ccIIV) influenza vaccines could improve seasonal influenza prevention; however, evidence is limited in how protection may differ among non-egg-based vaccines. Methods: We conducted a randomized trial of RIV versus ccIIV to compare vaccine immunogenicity in adults aged 18 to 64 years during the 2024-25 influenza season (ClinicalTrials.gov, NCT06518577 ). Active surveillance for influenza-like illness was conducted for six months post-vaccination and cumulative incidence of influenza by vaccine type was compared to estimate relative vaccine efficacy. Participants were tested for influenza by reverse-transcription polymerase chain reaction or rapid antigen tests. Immunogenicity was evaluated by hemagglutination inhibition (HAI), virus microneutralization (MN), and neuraminidase inhibition (NAI) assays in a subset of blood specimens collected pre-vaccination and one-month post-vaccination. Results: Among the 591 participants, 25 cases of influenza A were detected; 2.4% cumulative incidence among RIV recipients versus 6.1% among ccIIV recipients. The probability of influenza was 61% lower with RIV than ccIIV (95% confidence interval: 7 to 84). Among 151 participants, post-vaccination HAI and MN titers vaccine components were higher among RIV recipients while NAI titers were higher among ccIIV recipients. Conclusions: RIV provided better protection than ccIIV against influenza A illness in adults during the U.S. 2024-2025 season.
Open AccessComparative immunogenicity and relative vaccine efficacy of recombinant and cell culture-based influenza vaccines: Results from a randomized trial of adults in the United States, 2024-2025
Background: Recombinant (RIV) and cell culture-based inactivated (ccIIV) influenza vaccines could improve seasonal influenza prevention; however, evidence is limited in how protection may differ among non-egg-based vaccines. Methods: We conducted a randomized trial of RIV versus ccIIV to compare vaccine immunogenicity in adults aged 18 to 64 years during the 2024-25 influenza season (ClinicalTrials.gov, NCT06518577 ). Active surveillance for influenza-like illness was conducted for six months post-vaccination and cumulative incidence of influenza by vaccine type was compared to estimate relative vaccine efficacy. Participants were tested for influenza by reverse-transcription polymerase chain reaction or rapid antigen tests. Immunogenicity was evaluated by hemagglutination inhibition (HAI), virus microneutralization (MN), and neuraminidase inhibition (NAI) assays in a subset of blood specimens collected pre-vaccination and one-month post-vaccination. Results: Among the 591 participants, 25 cases of influenza A were detected; 2.4% cumulative incidence among RIV recipients versus 6.1% among ccIIV recipients. The probability of influenza was 61% lower with RIV than ccIIV (95% confidence interval: 7 to 84). Among 151 participants, post-vaccination HAI and MN titers vaccine components were higher among RIV recipients while NAI titers were higher among ccIIV recipients. Conclusions: RIV provided better protection than ccIIV against influenza A illness in adults during the U.S. 2024-2025 season.
- Open Access
- 1 September 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (9)
Detection and characterization of antiviral-resistant viruses during the influenza season of 2024–25
During the high severity season of 2024–25, CDC with public health partners sequenced and analyzed genomes of >10,000 influenza viruses for antiviral resistance markers. Available sequence-flagged and representative viruses were tested with antivirals using in vitro assays. In the US, three oseltamivir-resistant A(H3N2) viruses had treatment-emergent neuraminidase (NA) mutations, either E119V or R292K. Oseltamivir-resistant A(H1N1)pdm09 viruses with NA-H275Y were detected in 15 states, albeit at a low frequency (0.53%). They belonged to several phylogenetic groups, with hemagglutinin (HA) subclade D.3.1 combined with either NA subclade D.1 or D.2 being most common. Based on shared sequence data, nearly all H275Y viruses from Australia, Canada, and Chile also belonged to these HA and NA subclades. Conversely, most H275Y viruses (68/81) from China belonged to HA subclade C.1.9 and NA subclade D and shared the permissive mutation R257K. Influenza polymerase acidic (PA) mutations conferring 4- to 92-fold decreased baloxavir susceptibility were detected in nine influenza A viruses. Viruses with PA-I38T showed mild attenuation of replicative fitness in three cell lines. Based on available data, NA-H275Y and PA-I38T viruses were collected from patients with no exposure to antivirals. Baseline susceptibility to all US-approved influenza antivirals remained largely unchanged compared to previous seasons. All swine-origin viruses detected in the US had adamantane resistance-conferring marker, M2-S31N, but remained susceptible to other approved antivirals. Monitoring antiviral susceptibility has substantially improved with increased sequencing capacities and bioinformatic support at public health laboratories. Information gained through influenza surveillance has been used to guide recommendations on antiviral use. IMPORTANCE: Circulation of influenza viruses with reduced susceptibility to antivirals can diminish the usefulness of medications prescribed for influenza. This study informs on the prevalence of drug-resistant influenza viruses in the US during the high severity season of 2024–25. It provides information on susceptibility profile to all approved antiviral medications and on replicative fitness of representative drug-resistant viruses. Most drug-resistant viruses were collected from patients who were not exposed to antivirals indicating their ability to transmit from human to human. Whole-genome sequence (WGS)-based analysis is the cornerstone for surveillance, and numerous laboratories have been utilizing this approach. However, CDC laboratory is the only laboratory in the US conducting phenotypic testing of circulating viruses needed to confirm the outcomes of sequence-based analysis and to identify new molecular markers of resistance. Data gathered through virologic surveillance give much-needed information on drug susceptibility of influenza viruses which are used to guide recommendations on antiviral use.
- 1 September 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (9)
Open AccessDetection and characterization of antiviral-resistant viruses during the influenza season of 2024–25
During the high severity season of 2024–25, CDC with public health partners sequenced and analyzed genomes of >10,000 influenza viruses for antiviral resistance markers. Available sequence-flagged and representative viruses were tested with antivirals using in vitro assays. In the US, three oseltamivir-resistant A(H3N2) viruses had treatment-emergent neuraminidase (NA) mutations, either E119V or R292K. Oseltamivir-resistant A(H1N1)pdm09 viruses with NA-H275Y were detected in 15 states, albeit at a low frequency (0.53%). They belonged to several phylogenetic groups, with hemagglutinin (HA) subclade D.3.1 combined with either NA subclade D.1 or D.2 being most common. Based on shared sequence data, nearly all H275Y viruses from Australia, Canada, and Chile also belonged to these HA and NA subclades. Conversely, most H275Y viruses (68/81) from China belonged to HA subclade C.1.9 and NA subclade D and shared the permissive mutation R257K. Influenza polymerase acidic (PA) mutations conferring 4- to 92-fold decreased baloxavir susceptibility were detected in nine influenza A viruses. Viruses with PA-I38T showed mild attenuation of replicative fitness in three cell lines. Based on available data, NA-H275Y and PA-I38T viruses were collected from patients with no exposure to antivirals. Baseline susceptibility to all US-approved influenza antivirals remained largely unchanged compared to previous seasons. All swine-origin viruses detected in the US had adamantane resistance-conferring marker, M2-S31N, but remained susceptible to other approved antivirals. Monitoring antiviral susceptibility has substantially improved with increased sequencing capacities and bioinformatic support at public health laboratories. Information gained through influenza surveillance has been used to guide recommendations on antiviral use. IMPORTANCE: Circulation of influenza viruses with reduced susceptibility to antivirals can diminish the usefulness of medications prescribed for influenza. This study informs on the prevalence of drug-resistant influenza viruses in the US during the high severity season of 2024–25. It provides information on susceptibility profile to all approved antiviral medications and on replicative fitness of representative drug-resistant viruses. Most drug-resistant viruses were collected from patients who were not exposed to antivirals indicating their ability to transmit from human to human. Whole-genome sequence (WGS)-based analysis is the cornerstone for surveillance, and numerous laboratories have been utilizing this approach. However, CDC laboratory is the only laboratory in the US conducting phenotypic testing of circulating viruses needed to confirm the outcomes of sequence-based analysis and to identify new molecular markers of resistance. Data gathered through virologic surveillance give much-needed information on drug susceptibility of influenza viruses which are used to guide recommendations on antiviral use.
- 23 December 2025
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 15 (1) , 2601372
Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses from humans in the United States, October 2024 to February 2025
Since October 2024, 55 human cases of influenza A(H5N1), clade 2.3.4.4b, were reported in the US. Sequencing of 46 viruses identified genotypes B3.13, D1.1, and D1.3. Genomes of viruses were analyzed for mutations associated with reduced antiviral susceptibility. Except for two, viruses from human cases were assessed as susceptible to antivirals and confirmed by in vitro susceptibility testing of representative viruses with M2 blockers, neuraminidase (NA) inhibitors, and the polymerase acidic (PA) inhibitor baloxavir. One D1.1 virus had an M2-S31N substitution, which conferred cross-resistance to M2 blockers. One B3.13 virus had a PA-I38M substitution and displayed 17-fold reduced baloxavir susceptibility in cell culture. In mice, baloxavir, given orally at 5, 15, and 45 mg/kg bid for 5 days starting at 2 hours post-infection, was notably less effective against the PA-I38M virus compared to the closely matched control virus, as shown by survival rate, time-to-death, weight loss, and viral replication in various organs. Replication of the PA-I38M virus was mildly attenuated in mice but not in cell culture. Viruses collected from animals also contained mutations associated with reduced antiviral susceptibility, including M2-S31N, PA-I38 T/M, and NA-H275Y, albeit at low frequency. Regardless of genotype, most mutations were found in NA. Using recombinant NA proteins generated from B3.13 and D1.1 backgrounds, we showed that among mutations that reduced susceptibility of NA inhibitors, only NA-H275Y had no effect on the enzyme's function. Spontaneous emergence of drug-resistant influenza viruses, especially those that maintain replicative fitness, pose persistent threat to human health and must be closely monitored.
- 23 December 2025
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 15 (1) , 2601372
Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses from humans in the United States, October 2024 to February 2025
Since October 2024, 55 human cases of influenza A(H5N1), clade 2.3.4.4b, were reported in the US. Sequencing of 46 viruses identified genotypes B3.13, D1.1, and D1.3. Genomes of viruses were analyzed for mutations associated with reduced antiviral susceptibility. Except for two, viruses from human cases were assessed as susceptible to antivirals and confirmed by in vitro susceptibility testing of representative viruses with M2 blockers, neuraminidase (NA) inhibitors, and the polymerase acidic (PA) inhibitor baloxavir. One D1.1 virus had an M2-S31N substitution, which conferred cross-resistance to M2 blockers. One B3.13 virus had a PA-I38M substitution and displayed 17-fold reduced baloxavir susceptibility in cell culture. In mice, baloxavir, given orally at 5, 15, and 45 mg/kg bid for 5 days starting at 2 hours post-infection, was notably less effective against the PA-I38M virus compared to the closely matched control virus, as shown by survival rate, time-to-death, weight loss, and viral replication in various organs. Replication of the PA-I38M virus was mildly attenuated in mice but not in cell culture. Viruses collected from animals also contained mutations associated with reduced antiviral susceptibility, including M2-S31N, PA-I38 T/M, and NA-H275Y, albeit at low frequency. Regardless of genotype, most mutations were found in NA. Using recombinant NA proteins generated from B3.13 and D1.1 backgrounds, we showed that among mutations that reduced susceptibility of NA inhibitors, only NA-H275Y had no effect on the enzyme's function. Spontaneous emergence of drug-resistant influenza viruses, especially those that maintain replicative fitness, pose persistent threat to human health and must be closely monitored.
- Open Access
- 11 October 2025
- Published by Elsevier in Antiviral Research
- Vol. 244, 106299
Antiviral susceptibility monitoring: testing algorithm, methods, and findings for influenza season, 2023–2024
- 11 October 2025
- Published by Elsevier in Antiviral Research
- Vol. 244, 106299
Open AccessAntiviral susceptibility monitoring: testing algorithm, methods, and findings for influenza season, 2023–2024
- Open Access
- 1 April 2025
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 31 (4) , 751-760
Antiviral Susceptibility of Influenza A(H5N1) Clade 2.3.2.1c and 2.3.4.4b Viruses from Humans, 2023–2024
Antiviral Susceptibility of H5N1 Viruses
- 1 April 2025
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 31 (4) , 751-760
Open AccessAntiviral Susceptibility of Influenza A(H5N1) Clade 2.3.2.1c and 2.3.4.4b Viruses from Humans, 2023–2024
Antiviral Susceptibility of H5N1 Viruses
- Open Access
- 1 November 2024
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 30 (11) , 2303-2312
Antiviral Susceptibility of Swine-Origin Influenza A Viruses Isolated from Humans, United States
Antiviral Susceptibility of Swine-Origin Influenza
- 1 November 2024
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 30 (11) , 2303-2312
Open AccessAntiviral Susceptibility of Swine-Origin Influenza A Viruses Isolated from Humans, United States
Antiviral Susceptibility of Swine-Origin Influenza
- Open Access
- 1 July 2024
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 30 (7) , 1410-1415
Multicountry Spread of Influenza A(H1N1)pdm09 Viruses with Reduced Oseltamivir Inhibition, May 2023–February 2024
PH1N1 with Reduced Oseltamivir Inhibition
- 1 July 2024
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 30 (7) , 1410-1415
Open AccessMulticountry Spread of Influenza A(H1N1)pdm09 Viruses with Reduced Oseltamivir Inhibition, May 2023–February 2024
PH1N1 with Reduced Oseltamivir Inhibition
- 2 May 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (5) , e0172723
Influenza C virus susceptibility to antivirals with different mechanisms of action
Antiviral susceptibility of influenza viruses was assessed using a high-content imaging-based neutralization test. Cap-dependent endonuclease inhibitors, baloxavir and AV5116, were superior to AV5115 against type A viruses, and AV5116 was most effective against PA mutants tested. However, these three inhibitors displayed comparable activity (EC 50 8–22 nM) against type C viruses from six lineages. Banana lectin and a monoclonal antibody, YA3, targeting the hemagglutinin-esterase protein effectively neutralized some, but not all, type C viruses.
- 2 May 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (5) , e0172723
Influenza C virus susceptibility to antivirals with different mechanisms of action
Antiviral susceptibility of influenza viruses was assessed using a high-content imaging-based neutralization test. Cap-dependent endonuclease inhibitors, baloxavir and AV5116, were superior to AV5115 against type A viruses, and AV5116 was most effective against PA mutants tested. However, these three inhibitors displayed comparable activity (EC 50 8–22 nM) against type C viruses from six lineages. Banana lectin and a monoclonal antibody, YA3, targeting the hemagglutinin-esterase protein effectively neutralized some, but not all, type C viruses.
- Open Access
- 15 September 2023
- Published by Elsevier in Antiviral Research
- Vol. 218, 105719
New insights into the neuraminidase-mediated hemagglutination activity of influenza A(H3N2) viruses
- 15 September 2023
- Published by Elsevier in Antiviral Research
- Vol. 218, 105719
Open AccessNew insights into the neuraminidase-mediated hemagglutination activity of influenza A(H3N2) viruses
- Open Access
- 24 July 2023
- Published by Elsevier in Antiviral Research
- Vol. 217, 105679
Antiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses isolated from birds and mammals in the United States, 2022
- 24 July 2023
- Published by Elsevier in Antiviral Research
- Vol. 217, 105679
Open AccessAntiviral susceptibility of clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses isolated from birds and mammals in the United States, 2022